Clinical trials
Hidradenitis Suppurativa clinical trials
Below are recruiting hidradenitis suppurativa clinical trials, each written for real people, not researchers. We’re tracking 56 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07213973RecruitingPhase 2
Study of povorcitinib for teens with hidradenitis suppurativa
This trial tests an oral medication called povorcitinib for adolescents aged 12–17 with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with standard treatments like antibiotics. It aims to see how well the drug works and if it's safe.
Birmingham, AlabamaAges 12–17 - NCT07414550Recruiting
Radiation therapy for hard-to-treat hidradenitis suppurativa
This trial tests if low-dose radiation therapy can help people with moderate to severe hidradenitis suppurativa (HS) that hasn't gotten better with other treatments. It's for those with sores in both armpits.
Cherry Hill, New JerseyAges 18 years+ - NCT07659769Recruiting
Global study on hidradenitis suppurativa
This study collects information from people with hidradenitis suppurativa (a skin condition causing painful lumps) to better understand the condition and improve care worldwide.
ZurichAges 14 years+ - NCT07007637Enrolling by invitationPhase 3
Long-Term Safety and Effectiveness of Sonelokimab for Hidradenitis Suppurativa
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Birmingham, AlabamaAges 12 years+ - NCT05821478RecruitingPhase 3
Antibiotics plan for hidradenitis stage 2 flares
This Phase 3 study tests whether an adapted antibiotic treatment works better than the standard approach to control hidradenitis suppurativa (HS) symptoms and flares. It may help people with stage 2 HS reduce active inflammation and flare-ups.
MarseilleAges 18–59 - NCT06895499RecruitingPhase 1/Phase 2
Testing a new drug for hidradenitis suppurativa
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
Jinan, ShandongAges 18 years+ - NCT07228390RecruitingPhase 2
Testing ritlecitinib for hidradenitis suppurativa in adults
This study tests an oral medicine called ritlecitinib for moderate to severe hidradenitis suppurativa (HS) in adults who haven't responded well to antibiotics. The goal is to see if it can reduce painful red lumps and improve quality of life.
Phoenix, ArizonaAges 18–75 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT04115566Recruiting
HS patient registry and sample storage study
This study enrolls people with hidradenitis suppurativa (HS) to better understand the condition over time and store optional health information and samples. Being in the registry may help researchers learn about patterns in HS and support future research.
San Francisco, CaliforniaAges 10 years+ - NCT06645821RecruitingEarly Phase 1
Cream for mild to moderate hidradenitis suppurativa
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
Norfolk, VirginiaAges 18 years+ - NCT07136467Recruiting
Understanding daily life with vitiligo, alopecia areata, or hidradenitis suppurativa
This study looks at how certain skin conditions affect daily life in teens and adults. Researchers want to understand the challenges people face with vitiligo, alopecia areata, or hidradenitis suppurativa by having participants fill out simple questionnaires.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 12 years+ - NCT06785779Recruiting
HS patient satisfaction after starting Cosentyx in Saudi clinics
This study measures how satisfied people with moderate to severe hidradenitis suppurativa (HS) feel with their treatment after starting Cosentyx. It is for adults in Saudi Arabia who have not taken Cosentyx before and are starting it as part of their routine care.
Riyadh, SAUAges 18–99 - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT07665437RecruitingPhase 3
Long-term safety study of remibrutinib for hidradenitis suppurativa
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Fort Smith, ArkansasAges 18–100 - NCT07748169Recruiting
Observational study of skin disease patients
This study looks at the health records of people with skin diseases to learn more about their care and outcomes. It may help improve future treatments.
Winston-Salem, North CarolinaAges Any age - NCT06855498RecruitingPhase 3
Rollover study for patients who took povorcitinib before
This study is for people who have already taken the study drug povorcitinib in a previous trial and found it helpful. It lets you continue receiving the treatment and allows doctors to keep tracking its long-term safety and effects.
Birmingham, AlabamaAges 18 years+ - NCT07543419Recruiting
Real-world Study of Secukinumab for Moderate to Severe Hidradenitis Suppurativa
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Ancona, ANAges 18–100 - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+ - NCT05243966Recruiting
Registry for soft tissue repair using a special matrix
This study is a registry that collects information from people who had soft tissue repair using a specific matrix and/or morcell material. It may help researchers understand how this approach performs in real-world care and patient outcomes over time.
Phoenix, ArizonaAges 18 years+ - NCT03146676Recruiting
OSU Dermatology Biorepository for donated skin tissue and data
This study collects and stores skin samples and related health information from people seen in OSU Dermatology clinics. It helps researchers better understand skin conditions and may lead to new treatments in the future.
Columbus, OhioAges Any age - NCT05928169Recruiting
Tracking how inflammatory skin conditions change over time
This study looks at what affects the “path” (trajectory) of long-lasting inflammatory skin conditions. It may help researchers understand why symptoms change and how treatments or factors influence those changes.
KielAges birth–80 years - NCT05994976Recruiting
Collecting skin samples from people with skin conditions
This study collects skin samples (like small biopsies or swabs) from people with certain skin conditions and from healthy volunteers. The samples help researchers learn more about these conditions and may lead to better treatments.
Montreal, QuebecAges 18 years+ - NCT06324552Recruiting
Skin cell function in HS patients
This study looks at how skin cells work in people with hidradenitis suppurativa (HS), a condition that causes painful lumps under the skin. It aims to understand the disease better, which might lead to improved treatments in the future.
InnsbruckAges Any age
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hidradenitis suppurativa?
- Yes. Clin2 currently lists 56 recruiting hidradenitis suppurativa studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hidradenitis suppurativa trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hidradenitis suppurativa trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.